期刊文献+

HIV整合酶抑制剂雷特格韦的合成 被引量:3

Synthesis of raltegravir as the HIV ingretase inhibitor
下载PDF
导出
摘要 目的探究雷特格韦的合成方法。方法以2-氨基-2-甲基丙腈盐酸盐为起始原料,经过苄氧羰基保护氨基、由腈转化成肟、环合形成嘧啶、N-甲基化、酯的胺解、氢气还原脱保护、再经酰化缩合成酰胺等一系列反应制备得到雷特格韦。结果与结论目标产物雷特格韦及部分中间体的化学结构经1H-NMR和MS确证,总收率为25.29%(以2-氨基-2-甲基丙腈盐酸盐计),高于文献收率(12.0%)。 Objective To find a route to synthesize raltegravir. Methods Using 2-amino-2-methyl acrylic nitrile hydrochlodide as starting material,raltegravir was synthesized by a series of reactions like amino group protection,converting nitrile into oxime,cyclization,N-methylation,ammonolysis,deprotection and amidation. Results and Conclusions Raltegravir and parts of intermediates were characterized by IR,MS,1H-NMR spectra,and total yield was 25. 29%( with 2-amino-2-methylacrylic nitrile hydrochloride),which was higher than that of report in literature(12. 0%).
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2016年第4期271-274,302,共5页 Journal of Shenyang Pharmaceutical University
基金 国家自然科学基金资助项目(21342006)
关键词 HIV整合酶抑制剂 雷特格韦 合成 表征 HIV ingretase inhibitor raltegravir synthesis chacterization
  • 相关文献

参考文献6

  • 1冯婧劼,张庆文,徐云根.抗HIV-1药物及其复方制剂研究新进展[J].药学进展,2012,36(12):539-546. 被引量:7
  • 2马帅,高文磊,赵俊,曹胜华.人类免疫缺陷病毒-1整合酶抑制剂的研究进展[J].中国药学杂志,2014,49(21):1877-1881. 被引量:5
  • 3VINCENZO S,ALESSIA P,FABIO B,et al.Discovery of raltegravir,a potent,selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection[J].J Med Chem,2008,51(18):5843-5855.
  • 4郭涤亮,刘冠男,李建,周宇,徐进宜,蒋华良,柳红.Raltegravir的合成工艺研究(英文)[J].中国药科大学学报,2009,40(4):297-301. 被引量:4
  • 5GUY R H,P PHILIP J P,ZHONGY L,et al.Development of a second-generation,highly efficient manufacturing route for the HIV integrase inhibitor raltegravir potassium[J].Org Process Res Dev,2011,15(1):73-83.
  • 6WANGZ W,WANGM X,YAO X,et al.Hydroxyl may not be indispensable for raltegravir:Design,synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors[J].Eur J Med Chem,2012,50:361-369.

二级参考文献59

  • 1胡玉钦.恩曲他滨的研究现状与应用前景[J].中外医疗,2008,27(20):135-136. 被引量:10
  • 2牟英迪,林振广,刘宜辉.抗HIV病毒感染新药——硫酸阿扎那韦[J].齐鲁药事,2007,26(4):253-253. 被引量:3
  • 3WHO. HIV/AIDS[EB/OL]. (2013-10-30)[2014-4-15]. http://www.who.int/mediacentre/factsheets/fs360/en/.
  • 4WHO. HIV/AIDS[EB/OL]. (2013-10-30)[2014-4-15]. http://www.who.int/features/qa/71/en/.
  • 5POMMIER Y, JOHNSON A A, MARCHAND C. Integrase inhibitors to treat HIV/AIDS[J]. Nat Rev Drug Discov, 2005, 4(3): 236-248.
  • 6WILKINSON T A, JANUSZYK K, PHILLIPS M L, et al. Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase[J]. J Biol Chem, 2009, 284(12): 7931-7939.
  • 7DOBARD C W, BRIONES M S, CHOW S A. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription[J]. J Virol, 2007, 81(18): 10037-10046.
  • 8LU R, GHORY H Z, ENGELMAN A. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase[J]. J Virol, 2005, 79(16): 10356-10368.
  • 9HAZUDA D J, YOUNG S D, GUARE J P, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques[J]. Science, 2004, 305(5683): 528-532.
  • 10HARE S, GUPTA S S, VALKOV E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer[J]. Nature, 2010, 464(7286): 232-236.

共引文献13

同被引文献5

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部